Two weeks after announcing the creation of a new vaccine factory in France and 610 million euros of investment, during a visit by Emmanuel Macron to its site in Marcy-l’Etoile (Rhône), Sanofi has presented, Monday, June 29, his ” 2020 reorganization project ” It plans to cut 1,700 jobs in Europe, spread over three years, including ” 750 to 1,060 In France, where the group still has a quarter of its workforce, or 25,000 people. The last plan, still in progress, dates back to June 2019, and involved nearly 470 people in France and Germany.
→ READ. Paracetamol formula should return to France
The new mainly concerns support and commercial functions, but also R & D positions. If no closure is planned among the 18 French factories, tertiary sites are affected, such as the Paris head office and the Val campus -de-Bièvre. The Strasbourg research center, which has around sixty employees, is also threatened.
Departures planned in France will be “ exclusively based on volunteering “, says management. A system of early retirement paid by the company should also be put in place. By proposing very advantageous financial conditions, Sanofi will undoubtedly have no difficulty in finding candidates to leave. ” In previous plans, there were even sometimes more requests than deleted positions, as many people want to leave the group. Explains a manager.
But in the current context, the pharmaceutical giant’s announcement goes badly and the unions denounce “ layoffs that have no place », In the words of Florence Faure, the CFDT delegate. Drug sales were boosted by the health crisis and Sanofi maintained this year the payment of a dividend to its shareholders for a total amount of around 4 billion euros. Sanofi receives “Each year 110 to 120 million euros in research tax credit”, also underlines Thierry Bodin, the CGT delegate.
These announcements were, however, expected. The group’s new chief executive, the British Paul Hudson, had announced in December, three months after his arrival, that he wanted to save two billion euros by 2022, notably with a disengagement in diabetes and the cardiovascular system for the benefit of l ‘oncology.
The objective is to refocus the Sanofi portfolio on around 100 drugs, three times less than today. The unions are also worried about the sale of the consumer health center, which notably manufactures Doliprane.